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1. Introduction
This guideline focuses on the pharmacotherapy of obsessive-
compulsive disorder (OCD). OCD is characterised by obsessions and 
compulsions. A number of other disorders are also characterised by 
repetitive thoughts and rituals and may also respond to modifications 
of standard OCD treatment. These so-called OCD spectrum disorders 
include body dysmorphic disorder (characterised by recurrent 
concerns with imagined ugliness), hypochondriasis (characterised 
by recurrent concerns with imagined illness), trichotillomania 
(characterised by recurrent hair-pulling), and obsessive-compulsive 
personality disorder.[1] The Diagnostic and Statistical Manual of Mental 
Disorders, Fifth Edition[2] has a new chapter on obsessive-compulsive 
and related disorders, which includes several of these conditions.
2. Diagnosis and clinical characteristics
Evidence indicates that OCD is commonly underdiagnosed and 
undertreated.[3] There is also the converse possibility that various 
disorders with intrusive symptoms, such as post-traumatic stress 
disorder or generalised anxiety disorder, can be misdiagnosed as 
OCD. Diagnostic criteria for OCD are provided in Table 1.[4] 
3. Assessment
Most patients with OCD have both obsessions (which increase anxiety) 
and compulsions (which aim to decrease anxiety), particularly given 
that the Diagnostic and Statistical Manual of Mental Disorders, Fifth 
Edition[2] definition of compulsion includes mental rituals. The most 
common obsessions centre around concerns of contamination, harm, 
hoarding, and sexual, somatic and religious preoccupations, while the 
most common compulsions include washing, checking, repeating, 
ordering, counting, and hoarding.[5] The disorder is highly comorbid 
with obsessive-compulsive and related disorders, major depressive 
disorder, anxiety disorders, alcohol dependence, eating disorders and 
tic disorders.[6,7] Evaluation should include assessment of symptom 
pattern, severity, and functional impairment. Comorbid Axis I and 
II disorders, including tic disorders, as well as medical conditions 
(including pregnancy) and disorders need to be accurately identified. 
There is growing evidence that OCD and/or tics in some patients, 
particularly children, are precipitated or exacerbated by streptococcal 
or other infections.[8]
Evaluation of the OCD patient also requires attention to 
psychosocial factors that may have precipitated or exacerbated 
OCD symptoms. For example, are family members involved in the 
patient’s rituals? What is the patient’s explanatory model of OCD - 
does he or she regard it as a sign of weakness or as evidence of brain 
dysfunction? 
4. Treatment
4.1 Treatment goals
The goals of treatment of OCD are to reduce symptom frequency and 
severity and to improve functioning and quality of life. Treatment 
goals also encompass minimising medication adverse effects, helping 
the patient develop coping strategies for their OCD and related 
stressors, and educating the patient and family regarding the disorder 
and its treatment.[7] 
4.2 General aspects of treatment
In this discussion, we assume that the patient is an adult. Nevertheless, 
there are increasing data on the pharmacotherapy of OCD in children. [9,10] 
Indeed, the algorithm (see Fig. 1 below) can readily be adapted for 
children, bearing in mind considerations such as differences in dosing 
and differences in risk-benefit determination (e.g. clinicians are less 
likely to use untested augmentation strategies in children). Consultation 
with a child psychiatrist may well be indicated in such cases.
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Table 1. Criteria for obsessive-compulsive disorder*
A. Either obsessions or compulsions:
Obsessions as defined by (1), (2), (3), and (4):
1.  Recurrent and persistent thoughts, impulses, or images that are 
experienced, at some time during the disturbance, as intrusive 
and inappropriate and that cause marked anxiety or distress
2. † The thoughts, impulses, or images are not simply excessive 
worries about real-life problems
3.  The person attempts to ignore or suppress such thoughts, 
impulses, or images, or to neutralise them with  some other 
thought or action
4.  †The person recognises that the obsessional thoughts, impulses, 
or images are a product of his or her own  mind (not imposed 
from without as in thought insertion)
Compulsions as defined by (1) and (2):
1.  Repetitive behaviours (e.g. hand washing, ordering, checking) 
or mental acts (e.g. praying, counting, repeating words silently) 
that the person feels driven to perform in response to an 
obsession, or according to rules that must be applied rigidly
2.  The behaviours or mental acts are aimed at preventing 
or reducing distress or preventing some dreaded event or 
situation; however, these behaviours or mental acts either are 
not connected in a realistic way with what they are designed to 
neutralise or prevent or are clearly excessive
B.  At some point during the course of the disorder, the person has 
recognised that the obsessions or compulsions are excessive or 
unreasonable
C.  The obsessions or compulsions cause marked distress, are time 
consuming (take more than 1 hour a day), or significantly interfere 
with the person’s normal routine, occupational (or academic) 
functioning, or usual social activities or relationships 
D. ‡ If another Axis I disorder is present, the content of the obsessions or 
compulsions is not restricted to it 
E.  The disturbance is not due to the direct physiological effects of a 
substance (e.g. a drug of abuse, a medication) or a general medical 
condition.
* Adapted from the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text 
Revision; DSM-IV-TR.[4] For educational purposes only..
† Omitted from the DSM-V[2]
‡ This has been changed in the DSM-V[2] ‘The disturbance is not better explained by the symptoms 
of another mental disorder.’
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The initial treatment of OCD can arguably be either medication or 
psychotherapy as both approaches are efficacious. Several factors 
may complicate OCD, thus impacting on decisions about the choice 
of pharmacotherapy and other interventions. The most important 
factors, along with their treatment implications, are listed below. 
In addition, prior response to treatment and patient preference are 
important considerations. 
4.2.1  Severity
Patients with severe symptoms may require brief hospitalisation 
to help contain symptoms. In general, however, the principles of 
behaviour therapy suggest that patients should attempt to continue 
with their ordinary daily routines where possible.
4.2.2  Melancholia
There is some evidence that tricyclic antidepressants (TCAs) may be more 
effective than selective serotionin reuptake inhibitors (SSRIs) in patients 
with depression accompanied by melancholic features[11] and in possibly 
related subgroups such as in-patients with depression,[11-13] although not 
all evidence is consistent.[14] Melancholic features of depression include 
loss of pleasure in activities, lack of reactivity to pleasurable stimuli, and 
various neurovegetative symptoms such as exacerbation of depression in 
the morning, early-morning awakening, and significant weight loss. The 
only TCA that is effective in OCD is clomipramine.
4.2.3 Tourette’s disorder
This disorder is characterised by both motor and vocal tics. Many 
patients with Tourette’s disorder have comorbid OCD. Although 
this OCD may respond to standard OCD treatments, additional 
medication that targets the tics (e.g. dopamine blockers such as 
haloperidol, pimozide, or risperidone) may be necessary for resolution 
of the range of symptoms that characterise the disorder.[15]
4.2.4 Pregnancy, lactation, menopause
Pharmacotherapy should ideally be avoided during pregnancy and 
lactation. Nevertheless, where clinical considerations outweigh the 
risk of medication, such intervention should be considered after 
consultation with a specialist. In particular, there is growing literature 
pointing toward the relative safety of fluoxetine in pregnancy.[16]
4.2.5 Comorbid medical disorders and medications
Clinicians need to be aware of the multiple interactions between 
medications used in the treatment of OCD and other medications, 
as well as the impact of a medication’s adverse effects on medical 
disorders. Fortunately, certain SSRIs have relatively few interactions 
with other medications, and the SSRIs as a class are well tolerated in 
most medical disorders.
4.3 Pharmacological treatment
Refer to 4.5 and 4.6 below.
4.4 Non-pharmacological treatment
Psycho-education as part of the management of OCD is crucial. 
Similarly, cognitive-behavioural therapy (CBT) is an important 
aspect of OCD treatment, whether used alone or in combination with 
medication.[17] CBT for OCD has been delivered in individual, group, 
and family therapy formats. The number and length of treatment 
sessions vary across different studies, but some guidelines recommend 
13 - 20 weekly sessions for most patients.[7] 
4.5 Acute treatment
Patient motivation and ability to comply with pharmacotherapy and/
or psychotherapy are important considerations in choosing a first-line 
treatment approach. CBT and serotonin reuptake inhibitors (SRIs) are 
both considered safe and effective first-line treatments for OCD.[5,7]
The decision of whether to commence CBT or an SRI will depend on 
a number of factors including the nature and severity of symptoms, 
presence of co-occurring psychiatric and medical comorbidity and 
their treatments, patients’ access to CBT, past treatment history, and 
patient preference.[5,7] CBT alone, consisting of exposure and response 
prevention, is recommended as initial treatment for a patient who is not 
too depressed, anxious, or severely ill to co-operate with this treatment 
modality, or who prefers not to take medications and is willing to engage 
with CBT. Initiating treatment with an SRI is recommended for a patient 
who has previously responded well to an SRI or other drug, prefers 
medication treatment or is not suited for CBT.[7] 
The first line of medication in the treatment of OCD should 
comprise an SRI. Consistent with growing evidence for the importance 
of serotonin in OCD, both clomipramine and the SSRIs appear 
to be more effective than the noradrenergic reuptake inhibitor, 
desipramine, in the treatment of OCD.[18,19] The efficacy and safety 
of clomipramine and the SSRIs in the treatment of OCD have been 
well researched, with studies indicating that at least half of patients 
will respond to one of these agents. The SRIs are also useful for 
body dysmorphic disorder, hypochondriasis, obsessive-compulsive 
symptoms in Tourette’s disorder, and possibly (albeit with relatively 
less robust responses) in hair-pulling disorder (trichotillomania), 
excoriation (skin-picking) disorder, so-called compulsive sexual 
behaviour, and pathological gambling.[20,21] Note, however, that other 
agents may be preferable as first-line options in some of these 
conditions, e.g. given recent data that N-acetyl-cysteine is useful in 
hair-pulling disorder, this is an important consideration.
An immediate question, however, is which SRI to use first. Given 
the apparent lack of differences in efficacy between the SRIs, the side-
effect profile of these agents may be an important issue in considering 
which agent to use first. Certainly, there are invariably fewer side-
effects during treatment with the SSRIs than during treatment 
with clomipramine. Therefore, it seems reasonable to suggest that 
treatment of OCD be initiated with an SSRI. 
While all SSRIs appear to have similar efficacy, individual patients 
may respond well to one medication and not to another. In choosing 
among the SSRIs, it is important to consider the safety and acceptability 
of particular side-effects for the patient, potential drug interactions, 
past treatment response, and the presence of co-occurring general 
medical conditions.[7] Low doses should initially be used in patients 
with comorbid panic disorder.
Most patients will not experience substantial improvement until 
4 - 6 weeks after initiating medication, and some patients who will 
ultimately respond will experience little improvement by 8 - 10 
weeks. [5,7] To determine response to medication, it is important to ask 
about change in those symptoms initially targeted for treatment. Side-
effects of the medication should also be determined, with particular 
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attention to those that patients may be reluctant to disclose (e.g. 
sexual dysfunction). It may be useful to complete a symptom rating 
scale (Table 2)[22] to help quantify response to medication.
Patients who are intolerant of a particular medication can of course 
be switched to another agent. Within the SRIs, adverse effects may not 
be seen when an alternative SSRI or clomipramine is used.
When there is a poor response to medication, it is important to 
optimise dosage and duration of the medication. Although some 
patients with OCD respond to standard doses of SRIs, others require 
doses that are much higher than in depression. In adults, clomipramine 
should be increased to approximately 250 mg, and the SSRIs should 
be increased to maximal dosages (e.g. 60 - 80 mg of fluoxetine) 
bearing in mind recent black box warnings (e.g. citalopram should 
not be increased higher than 40 mg). Unfortunately, the likelihood of 
side-effects also increases at these doses. Electrocardiogram (ECG) 
monitoring may be necessary when children and adolescents, or 
patients with pre-existing heart disease, are treated with clomipramine.
Response to SSRIs in OCD may take rather longer than in many 
other disorders - up to 12 weeks. It is obviously important to give 
each patient a trial of medication that is of adequate duration. Patients 
therefore need to be educated that response may take a significant 
length of time and that they need to remain optimistic even when no 
change is seen at first.
At the end of a clinical trial of optimal dose and duration, patients 
should be thoroughly reassessed. There is growing recognition of 
the importance of residual anxiety symptoms in causing disability 
and predicting relapse, and of the consequent necessity of aiming for 
remission of symptoms as the endpoint of treatment.[23] Nevertheless, 
many OCD patients who are judged ‘responders’ to medication 
therapy may continue to experience obsessions and compulsions, 
albeit with less intensity. In clinical trials, a decrease of 25 - 35% on the 
Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) may correspond 
to a categorical treatment response.[22]
4.6 Maintenance treatment
In patients where an SRI is effective, maintenance pharmacotherapy 
should be instituted. Rapid discontinuation of these agents risks the 
return of symptoms. Nevertheless, a maintenance dose of SSRIs in OCD 
may be lower than the dose initially required during acute treatment. [21] 
At least a year of maintenance pharmacotherapy is reasonable. When 
a decision is made to attempt discontinuation of medication, it is 
advisable to taper medication off slowly (e.g. by 25% every 2 months). 
Concomitant behavioural treatment (exposure therapy and response 
prevention) during pharmacotherapy may well increase chances of 
being able to discontinue medication without relapse.
4.7 Managing partial and non-responders
Comparison of augmentation with switching strategies in OCD has not 
been well researched. Augmentation offers the advantage of retaining 
any possible gains from the first agent, but the potential disadvantages 
of polypharmacy (more side-effects, drug interactions). [24] Of all the 
augmentation strategies in the treatment of OCD, perhaps the most 
important is augmentation of pharmacotherapy with additional 
psychotherapy.[25] 
Combined SRI and CBT treatment can be considered when the 
patient has a co-occurring disorder that is SRI-responsive or has a 
partial response to monotherapy. Combination of an SRI and CBT may 
also reduce the chance of relapse when medication is discontinued. In 
patients who have had a partial response to CBT monotherapy, it may 
be useful to increase the intensity of treatments.[7]
However, when there is a partial response despite an optimum trial of 
medication, or when there are comorbid tics, it may be useful to consider 
augmentation. Certainly, in patients with comorbid tics, there is good 
evidence that augmentation of an SRI with a dopamine blocker can be 
effective.[26] About one-third to one-half of treatment-refractory OCD 
patients will have a meaningful treatment response to antipsychotic 
augmentation. The introduction of the new-generation antipsychotics 
has led to increased use of these agents in the augmentation therapy 
of OCD, and they appear useful in treatment-refractory patients even 
in the absence of comorbid tics. [27-29] Another possible strategy is to 
supplement an SSRI with a low dose of clomipramine,[30] although careful 
monitoring of adverse effects and ECGs may be warranted with such a 
combination. Other augmentation strategies have been suggested, but 
there are few positive controlled trials. There is also relatively little work 
on augmentation strategies in OCD-related disorders, although addition 
of a dopamine blocker may also be useful in some of these patients.[31]
When OCD does not respond to a clinical trial of optimal dose and 
duration, it is useful to reassess a number of factors. The presence 
of certain features may impact on the choice of the subsequent 
intervention.
4.7.1 Compliance
Clinicians often overestimate the compliance of their patients and 
it is often useful to check with patients and their families whether 
medication is being taken as prescribed. Many patients worry that 
medication is addictive or is a ‘crutch’.
4.7.2 Comorbid substance use
In patients who fail to respond to pharmacotherapy, the possibility of 
comorbid substance use should again be considered. There may be a 
need for withdrawal before tackling the OCD per se.[32,33]
4.7.3 Comorbid personality disorders
Although SSRIs may be useful, additional interventions such as 
psychotherapy may be crucial in patients with OCD and comorbid 
personality disorder. While improvement in OCD symptoms may 
reduce maladaptive behaviour in comorbid personality disorder, the 
personality disorder itself may need to be a major target of treatment.
4.7.4 Underlying medical disorder
Patients with obsessive-compulsive and related disorders who 
fail to respond to medication should be thoroughly reassessed for 
an underlying medical disorder. In OCD in children, the role of 
streptococcal throat infection may be particularly important.
4.7.5 Pharmacokinetic issues
Drug-drug interactions may result in a subtherapeutic dose of the 
prescribed antidepressant.
4.7.6 Psychosocial issues
Psychosocial circumstances that continue to complicate the course 
of OCD need to be assessed, as these may necessitate appropriate 
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Table 2. Yale-Brown Obsessive-Compulsive Scale[22]
Question Answer scale
‘I am now going to ask several questions about your obsessive thoughts.’ 
(Make specific reference to the patient’s target obsessions)
1.  Time occupied by obsessive thoughts
Q:  How much of your time is occupied by obsessive thoughts?  
How frequently do the obsessive thoughts occur?
0 = None.
1 = Mild, less than 1 hour/day or occasional intrusion.
2 = Moderate, 1 to 3 hours/day or frequent intrusion.
3 = Severe, greater than 3 and up to 8 hours/day or very frequent intrusion.
4 = Extreme, greater than 8 hours/day or near constant intrusion.
2.  Interference due to obsessive thoughts
Q:  How much do your obsessive thoughts interfere with your social 
or work (or role) functioning? Is there anything that you don’t do 
because of them?
0 = None.
1 = Mild, slight interference with social or occupational activities, but 
overall performance not impaired.
2 = Moderate, definite interference with social or occupational 
performance, but still manageable.
3 = Severe, causes substantial impairment in social or occupational 
performance.
4 = Extreme, incapacitating.
3.  Distress associated with obsessive thoughts
Q:  How much distress do your obsessive thoughts cause you?
0 = None.
1 = Mild, not too disturbing.
2 = Moderate, disturbing, but still manageable.
3 = Severe, very disturbing.
4 = Extreme, near constant and disabling distress.
4.  Resistance against obsessions 
Q:  How much of an effort do you make to resist the obsessive thoughts? 
How often do you try to disregard or turn your attention away from 
these thoughts as they enter your mind?
0 = Makes an effort to always resist, or symptoms so minimal doesn’t need 
to actively resist.
1 = Tries to resist most of the time.
2 = Makes some effort to resist.
3 = Yields to all obsessions without attempting to control them, but does so 
with some reluctance.
4 = Completely and willingly yields to all obsessions.
5.  Degree of control over obsessive thoughts
Q:  How much control do you have over your obsessive thoughts? How 
successful are you in stopping or diverting your obsessive thinking? 
Can you dismiss them?
0 = Complete control.
1 = Much control, usually able to stop or divert obsessions with some effort 
and concentration.
2 = Moderate control, sometimes able to stop or divert obsessions.
3 = Little control, rarely successful in stopping or dismissing obsessions, 
can only divert attention with difficulty.
4 = No control, experienced as completely involuntary, rarely able to even 
momentarily alter obsessive thinking.
The next several questions are about your compulsive behaviours.’ (Make 
specific reference to the patient’s target compulsions)
6.  Time spent performing compulsive behaviours
Q:  How much time do you spend performing compulsive behaviours? 
How much longer than most people does it take to complete routine 
activities because of your rituals? How frequently do you perform 
compulsions?
0 = None.
1 = Mild (spends less than 1 hour/day performing compulsions), or 
occasional performance of compulsive behaviours.
2 = Moderate (spends from 1 to 3 hours/day performing compulsions), or 
frequent performance of compulsive behaviours.
3 = Severe (spends more than 3 and up to 8 hours/day performing 
compulsions), or very frequent performance of compulsive behaviours.
4 = Extreme (spends more than 8 hours/day performing compulsions), or 
near constant performance of compulsive behaviours (too numerous to 
count).
continued...
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intervention. In particular, the participation of friends and family in 
rituals may serve to derail treatment.
After the failure of an adequate clinical trial of medication in a 
patient where reassessment sheds no light on any further unresolved 
factors, a different agent should be used. Although an SRI has 
less chance of being effective in patients who have already failed a 
number of trials of other SRIs, some of these patients (approximately 
one-third of non-responders to initial SRI monotherapy) will in fact 
ultimately respond to a new SRI.[34] Given the possible superiority 
of clomipramine in certain cases of OCD and depression, it may be 
argued that all OCD patients who have failed to respond to one or 
more of the SSRIs deserve a trial of clomipramine.[35] While results 
of studies correlating plasma drug levels and therapeutic response in 
OCD have been mixed, in the case of clomipramine obtaining drug 
levels at high doses may be useful. Anecdotal experience suggests 
that certain non-SRI agents, such as the classic monoamine oxidase 
inhibitors and venlafaxine, may on occasion be effective in treatment-
resistant OCD.[36] Recent trials of intravenous clomipramine also 
show efficacy in treatment-resistant OCD.[37]
For patients who have failed multiple medication and behavioural 
treatments (including intensive partial or full hospitalisation 
programmes),[38] and where severity of the disorder is marked, 
neurosurgery should also be considered.[39] Several studies have 
suggested that specific lesions to or deep-brain stimulation of 
components of corticostriatal and related pathways may lead to 
significant reduction in OCD symptoms in treatment-refractory 
Table 2 (continued). Yale-Brown Obsessive-Compulsive Scale[22]
Question Answer scale
7.  Interference due to compulsive behaviours 
Q:  How much do your compulsive behaviours interfere with your social 
or work (or role) functioning? Is there anything that you don’t do 
because of the compulsions?
0 = None.
1 = Mild, slight interference with social or occupational activities, but 
overall performance not impaired.
2 = Moderate, definite interference with social or occupational 
performance, but still manageable.
3 = Severe, causes substantial impairment in social or occupational 
performance.
4 = Extreme, incapacitating.
8.  Distress associated with compulsive behaviour
Q:  How would you feel if prevented from performing your 
compulsion(s)? How anxious would you become? How anxious do 
you get while performing compulsions until you are satisfied they are 
completed?
0 = None.
1 = Mild, only slightly anxious if compulsions prevented, or only slight 
anxiety during performance of compulsions.
2 = Moderate, reports that anxiety would mount but remain manageable if 
compulsions prevented, or that anxiety increases but remains manageable 
during performance of compulsions.
3 = Severe, prominent and very disturbing increase in anxiety if 
compulsions interrupted, or prominent and very disturbing increase in 
anxiety during performance of compulsions.
4 = Extreme, incapacitating anxiety from any intervention aimed at 
modifying activity, or incapacitating anxiety develops during performance 
of compulsions.
9.  Resistance against compulsions 
Q:  How much of an effort do you make to resist the compulsions?
0 = Makes an effort to always resist, or symptoms so minimal doesn’t need 
to actively resist.
1 = Tries to resist most of the time.
2 = Makes some effort to resist.
3 = Yields to almost all compulsions without attempting to control them, 
but does so with some reluctance.
4 = Completely and willingly yields to all compulsions.
10.  Degree of control over compulsive behaviour
 Q:  How strong is the drive to perform the compulsive behaviour? How 
much control do you have over the compulsions?
0 = Complete control.
1 = Much control, experiences pressure to perform the behaviour but 
usually able to exercise voluntary control over it.
2 = Moderate control, strong pressure to perform behaviour, can control it 
only with difficulty.
3 = Little control, very strong drive to perform behaviour, must be carried 
to completion, can only delay with difficulty.
4 = No control, drive to perform behaviour experienced as completely 
involuntary and overpowering, rarely able to even momentarily delay 
activity.
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patients. Patients can be referred to specialised 
centres for such treatments. 
5. Algorithm
Fig. 1 outlines the treatment.
6. Summary points
• CBT and the serotonin reuptake inhibitors 
(SRIs), clomipramine and the SSRIs, are 
efficacious and safe first-line treatments 
for OCD.
• Whether to commence CBT or an SRI 
will depend on the nature and severity 
of symptoms, presence of co-occurring 
psychiatric and medical comorbidities 
and their treatments, a patient’s access to 
CBT, past treatment history, and patient 
preference.
• CBT alone, consisting of exposure and 
response prevention, is recommended 
as first-line for a patient who is not 
too depressed, anxious, or severely ill to 
co-operate with this treatment modality, or 
who prefers not to take medications and is 
willing to engage with CBT.
• SRI first-line treatment is recommended for 
a patient who has previously responded well 
to an SSRI or other drug, prefers medication 
treatment, or is not suited for CBT.
• Most patients will not experience substantial 
improvement until 4 - 6 weeks after 
initiating medication, and some patients 
who ultimately respond will experience little 
improvement by 8 - 10 weeks.
• Although some patients with OCD respond 
to standard doses of SRIs, others require 
doses that are much higher than those used 
for depression. In adults, clomipramine 
should be increased to approximately 250 
mg, and the SSRIs should be increased to 
maximal safe dosages (e.g. 60 - 80 mg of 
fluoxetine).
• At least a year of maintenance 
pharmacotherapy is reasonable in patients 
who respond to medication.
• CBT (exposure and response prevention) 
can be used alone or in combination 
with medication. Psycho-education is also 
crucial.
• When there is a partial response to an 
optimal trial of medication, or when 
there are comorbid tics, it may be useful 
to consider augmentation. Many OCD 
patients will have a meaningful treatment 
response to antipsychotic augmentation. 
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Fig. 1. Algorithm for pharmacotherapy of obsessive-compulsive disorder.[40]
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